Sanofi-Aventis is restructuring its R&D operation and plans to close eight of its 27 R&D sites. The new R&D model, which is expected to be in place by 2013, aims to group researchers in more productive structures, working more closely with academics and hospitals to help drive innovation. The company will focus on diabetes, cancer and age-related diseases as well as anti-inflammatory and anti-infectious diseases, according to Christian Lajoux, head of Sanofi-Aventis France. Under ...